Compact Cyclotron and Microfluidic Synthesis for Radiopharmaceutical Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cyclotrons for radiopharmaceutical production are large, power-intensive, and costly, making on-site production impractical for most medical facilities, and they have inefficiencies in processing time and yield due to the short half-lives of positron-emitting isotopes.
Innovation Solution
A compact, low-power particle accelerator combined with a radiopharmaceutical micro-synthesis system using microreactors and microfluidic chips, optimized to produce radioisotopes in quantities suitable for a unit dose, reducing size, weight, and power requirements, and incorporating permanent magnets and an internal target to minimize radiation and infrastructure needs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional cyclotrons are used for radiopharmaceutical production, then sufficient radioisotope quantity can be produced, but the system becomes large, heavy, and power-intensive
Solution Approach 1:
The patent divides the radiopharmaceutical production system into two independent segments: a compact cyclotron for radioisotope production and a separate microfluidic synthesis system for radiopharmaceutical fabrication. This segmentation allows the cyclotron to be miniaturized while maintaining production capability, as it only needs to generate the radioisotope rather than handle the entire synthesis process.
Solution Approach 2:
The patent introduces a microfluidic chip as an intermediary component that receives the produced radioisotope and performs the chemical synthesis. This intermediary handles the bulk of the processing work, allowing the cyclotron itself to remain small while still achieving sufficient overall production through the coordinated action of both components.
2Quantity of substance
If conventional cyclotrons are used for radiopharmaceutical production, then radioisotopes can be produced, but substantial electrical power and infrastructure are required
Solution Approach 1:
The patent segments the power-intensive production process into two stages: a low-power compact cyclotron that produces the radioisotope and a microfluidic synthesis system that consumes minimal power for chemical reactions. This segmentation dramatically reduces overall power requirements compared to a single large conventional cyclotron system.
Solution Approach 2:
The patent changes the operational parameters of the cyclotron by optimizing it for producing smaller quantities of radioisotope at higher specific activities, which is sufficient for modern radiopharmaceutical applications. This parameter optimization allows the cyclotron to operate at lower power levels while still meeting clinical needs.
3Quantity of substance
If large reaction vessels are used in radiochemical synthesis, then sufficient radiopharmaceutical can be produced, but processing time increases which reduces yield due to short half-lives
Solution Approach 1:
The patent transitions from conventional macro-scale batch reaction vessels to micro-scale fluidic channels, effectively moving the reaction system to a different dimensional regime. This miniaturization increases the surface-area-to-volume ratio, dramatically improving heat and mass transfer rates and reducing processing time while maintaining sufficient production quantity.
Solution Approach 2:
The patent changes the physical parameters of the reaction system by using microfluidic dimensions, which fundamentally alters the kinetics and transport phenomena. The reduced diffusion distances and enhanced surface area to volume ratio in the microfluidic system accelerate reaction rates and reduce processing time, directly addressing the half-life constraint.
4Productivity
If conventional radiochemical synthesis systems are used, then radiopharmaceuticals can be produced, but facility size and construction costs are substantial
Solution Approach 1:
The patent segments the production system into a compact cyclotron and a miniaturized microfluidic synthesis module, each optimized for its specific function. This segmentation eliminates the need for large conventional facility infrastructure while maintaining full radiopharmaceutical production capability, as each component is independently optimized and space-efficient.
Solution Approach 2:
The patent replaces the conventional mechanical batch processing system with an integrated microfluidic system that uses fluid dynamics and surface chemistry for synthesis. This substitution eliminates the need for large reaction vessels, mechanical stirring apparatus, and associated infrastructure, dramatically reducing facility volume requirements.
Data Source
AI summary
An improved biomarker generator and a method suitable for efficiently producing short lived radiopharmaceuticals in quantities on the order of a unit dose. The improved biomarker generator includes a particle accelerator and a radiopharmaceutical micro-synthesis system. The micro-accelerator of the improved biomarker generator is optimized for producing radioisotopes useful in synthesizing radiopharmaceuticals in quantities on the order of one unit dose allowing for significant reductions in size, power requirements, and weight when compared to conventional radiopharmaceutical cyclotrons. The radiopharmaceutical micro-synthesis system of the improved biomarker generator is a small volume chemical synthesis system comprising a microreactor and/or a microfluidic chip and optimized for synthesizing the radiopharmaceutical in quantities on the order of one unit dose allowing for significant reductions in the quantity of radioisotope required and the processing time when compared to conventional radiopharmaceutical processing systems.